Convergence of a diabetes mellitus, protein energy malnutrition, and TB epidemic : the neglected elderly population by Menon, Sonia et al.
REVIEW Open Access
Convergence of a diabetes mellitus, protein
energy malnutrition, and TB epidemic: the
neglected elderly population
Sonia Menon1,2*, Rodolfo Rossi3, Leon Nshimyumukiza4, Aibibula Wusiman5, Natasha Zdraveska6
and Manal Shams Eldin7
Abstract
Background: On a global scale, nearly two billion persons are infected with Mycobacterium tuberculosis. From this
vast reservoir of latent tuberculosis (TB) infection, a substantial number will develop active TB during their lifetime, with
some being able to transmit TB or Multi-drug- resistant (MDR) TB to others. There is clinical evidence pointing to a
higher prevalence of infectious diseases including TB among individuals with Diabetes Mellitus (DM). Furthermore,
ageing and diabetes mellitus may further aggravate protein-energy malnutrition (PEM), which in turn impairs T-
lymphocyte mediated immunologic defenses, thereby increasing the risk of developing active TB and compromising
TB treatment. This article aims to a) highlight synergistic mechanisms associated with immunosenescence, DM and
PEM in relation to the development of active TB and b) identify nutritional, clinical and epidemiological research gaps.
Methods: To explore the synergistic relationship between ageing, DM, tuberculosis and PEM, a comprehensive review
was undertaken. The MEDLINE and the Google Scholar databases were searched for articles published from 1990 to
March 2015, using different MESH keywords in various combinations.
Results: Ageing and DM act synergistically to reduce levels of interferon gamma (IFN- γ), thereby increasing
susceptibility to TB, for which cell mediated immunity (CMI) plays an instrumental role. These processes can set in
motion a vicious nutritional cycle which can predispose to PEM, further impairing the CMI and consequently
limiting host defenses. This ultimately transforms the latent TB infection into active disease. A clinical diagnostic
algorithm and clinical guidelines need to be established for this population.
Conclusion: Given the increase in ageing population with DM and PEM, especially in resource-poor settings, these
synergistic tripartite interactions must be examined if a burgeoning TB epidemic is to be averted. Implementation of a
comprehensive, all-encompassing approach to curb transmission is clearly indicated. To this end, clinical, nutritional
and epidemiological research gaps must be addressed without a delay.
Background
TB infection occurs when a susceptible person inhales
droplets containing Mycobacterium tuberculosis bacteria,
which travel through the respiratory tract to the alveoli.
In most patients, host’s immune response limits the
propagation of TB infection, resulting in an asymptom-
atic, non-transmissible localized infection that may
remain in the body for many years, if not forever.
One in three people in the world has latent tubercu-
losis [1]. In 2009, approximately 9 million new cases of
active TB were diagnosed and 1.7 million persons suc-
cumbed to the disease [2]. An additional challenge to
TB control efforts is the global increase in multi-drug
resistant TB (MDR-TB), defined as TB caused by strains
resistant to at least isoniazid and rifampin. In 2013, the
World Health Organization (WHO) reported that 3.6 %
of the new cases and 20.2 % of the previously treated
cases had MDR-TB [3].
Concurrently, diabetes mellitus (DM) is burgeoning as
a worldwide chronic health condition, which can be
attributed to increases in obesity, changing patterns of
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diet and physical activity as well as ageing [4, 5]. Accord-
ing to WHO estimates, there are currently 347 million
people worldwide affected by DM, [6] and by 2030 its
prevalence is projected to increase by 50 % [6]. 3/4 of
diabetic patients live in low-income countries [7–9]. It is
now well-established that cellular immune responses
mediated by T cells and macrophages play a major role
in the defense against TB [10]. In particular, the Th1
cytokine interferon (IFN)-γ is considered a principal me-
diator of protective immunity against TB [11, 12]
DM is a clinical syndrome associated with deficiency
of insulin secretion or resistance to its actions. Apart
from the classical micro and macrovascular complica-
tions of the disease, DM has been associated with re-
duced T cell response and neutrophil functional activity
as well as humoral immunity disorders, [13, 14] which
in turn compromises the protective role that cellular
immune response plays against TB. Consequently, DM
patients show increased susceptibility to infections, not-
ably TB, compared to individuals without DM [2, 15].
Some studies have shown that TB/DM comorbidity is
common, both in low-income and high-income coun-
tries. [2, 16]. A 2008 systematic review of literature
which identified 13 age-adjusted, quantitative, observa-
tional studies in North America, UK, Russia, Mexico,
Korea, Taiwan and India reported a relative risk of TB in
DM patients of 3.1 in cohort studies, with odds ratios
ranging from 1.16 to 7.83 in case control studies [17].
An epidemiological model indicated that in India DM
might account for nearly 15 % of pulmonary tuberculosis
(PTB) cases [18].
In diabetic patients, pulmonary TB may progress rap-
idly and hence requires a high index of suspicion in the
diagnostic phase [19].
Furthermore, the rising number of ageing diabetic
population at risk for TB represents a worldwide health
threat. People aged 60 and older make up over 11 % of
the global population and by 2050 that number is ex-
pected to rise to about 22 % [20]. By 2050, 4 out of 5
people over 60 will live in developing countries [21]. In
this population group, approximately 90 % of TB cases
are due to reactivation of primary infection [22].
Ageing is associated with a decline in T cell prolifera-
tion and reduced synthesis of interferon gamma (IFN-γ),
[23] which compromises body’s protective defenses
against TB. In turn, by compounding the decrease in
IFN – γ DM predisposes the ageing patient to infections
where cell-mediated immunity plays a pivotal role, such
as tuberculosis.
Moreover, ageing and DM act synergistically and
further aggravate protein-energy malnutrition (PEM),
which is common in chronic disease states and is associ-
ated with increased morbidity and mortality [24]. This
tripartite interaction additionally impairs T-lymphocyte
mediated immunologic defenses, increasing the risk of
certain infectious diseases [25]. According to the WHO,
the number of people with TB attributable to PEM may
exceed the number of people whose TB develops sec-
ondary to HIV infection, smoking or DM [26]. The
negative impact of undernutrition on cell-mediated im-
munity is well documented [25, 27–29]. Malnutrition
and infection interact with each other synergistically. Re-
current TB may cause loss of body nitrogen and wors-
ened nutritional status. The resulting malnutrition may
in turn increase the susceptibility to recurrent infection.
Using data from existing literature, this article aims to
highlight the synergistic mechanisms associated with
immunosenescence and DM in relation to development
of active TB. This includes the possible association be-
tween ageing and development of TB and/or PEM and
the possible association between TB and PEM. The pos-
sibility of treatment for latent TB in the ageing popula-
tion with DM is also explored.
Finally, this paper aims to identify the clinical and epi-
demiological research gaps which need to be addressed
in order to curb transmission.
Method
To explore the synergistic relationship between ageing,
DM, tuberculosis and PEM, the MEDLINE and the
Google Scholar databases were searched for articles pub-
lished from 1960 to March 2015. The following key-
words were identified using medical subject headings
and truncations:
Synergistic biological mechanisms between DM, ageing
TB population and PEM
Ageing and TB
("ageing"[MeSH Terms] OR "ageing"[All Fields]) AND
("tuberculosis"[MeSH Terms] OR "tuberculosis"[All
Fields]) yields 523 results
Ageing and DM
("ageing"[MeSH Terms] OR "ageing"[All Fields]) AND
("diabetes mellitus"[MeSH Terms] OR ("diabetes"[All
Fields] AND "mellitus"[All Fields]) OR "diabetes mellitu-
s"[All Fields]) yields 8131 results
Ageing and PEM
("ageing"[MeSH Terms] OR "ageing"[All Fields]) AND
("protein-energy malnutrition"[MeSH Terms] OR ("pro-
tein-energy"[All Fields] AND "malnutrition"[All Fields])
OR "protein-energy malnutrition"[All Fields] OR ("pro-
tein"[All Fields] AND "energy"[All Fields] AND "malnu-
trition"[All Fields]) OR "protein energy malnutrition"[All
Fields]) yields 363 results
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PEM and TB
("protein-energy malnutrition"[MeSH Terms] OR ("pro-
tein-energy"[All Fields] AND "malnutrition"[All Fields])
OR "protein-energy malnutrition"[All Fields] OR ("pro-
tein"[All Fields] AND "energy"[All Fields] AND "malnu-
trition"[All Fields]) OR "protein energy malnutrition"[All
Fields]) AND ("tuberculosis"[MeSH Terms] OR "tuber-
culosis"[All Fields] yields 91 results
BMI and TB
BMI[All Fields] AND TB[All Fields] yields 2666 results.
Treatment of latent TB in ageing population with DM
("therapy"[Subheading] OR "therapy"[All Fields] OR
"treatment"[All Fields] OR "therapeutics"[MeSH Terms]
OR "therapeutics"[All Fields]) AND ("latent tuberculo-
sis"[MeSH Terms] OR ("latent"[All Fields] AND "tuber-
culosis"[All Fields]) OR "latent tuberculosis"[All Fields]))
AND ("ageing"[MeSH Terms] OR "ageing"[All Fields])]
yields 19 results
Diabetes mellitus and multi drug resistant TB
("diabetes mellitus"[MeSH Terms] OR ("diabetes"[All
Fields] AND "mellitus"[All Fields]) OR "diabetes mellitu-
s"[All Fields]) AND multi [All Fields] AND ("drug
resistance"[MeSH Terms] OR ("drug"[All Fields] AND
"resistance"[All Fields]) OR "drug resistance"[All Fields]
OR ("drug"[All Fields] AND "resistant"[All Fields]) OR
"drug resistant"[All Fields]) AND TB. [All Fields] yields
19 results
Diabetes mellitus and multi-drug resistant TB treatment
("diabetes mellitus"[MeSH Terms] OR ("diabetes"[All
Fields] AND "mellitus"[All Fields]) OR "diabetes mellitu-
s"[All Fields]) AND multi[All Fields] AND ("drug resis-
tance"[MeSH Terms] OR ("drug"[All Fields] AND
"resistance"[All Fields]) OR "drug resistance"[All Fields]
OR ("drug"[All Fields] AND "resistant"[All Fields]) OR
"drug resistant"[All Fields]) AND TB[All Fields] AND
("therapy"[Subheading] OR "therapy"[All Fields] OR
"treatment"[All Fields] OR "therapeutics"[MeSH Terms]
OR "therapeutics"[All Fields]) yields 15 results
DM and PEM
"diabetes mellitus"[MeSH Terms] OR ("diabetes"[All
Fields] AND "mellitus"[All Fields]) OR "diabetes mellitu-
s"[All Fields]) AND ("protein-energy malnutrition"[-
MeSH Terms] OR ("protein-energy"[All Fields] AND
"malnutrition"[All Fields]) OR "protein-energy malnutri-
tion"[All Fields] OR ("protein"[All Fields] AND "ener-
gy"[All Fields] AND "malnutrition"[All Fields]) OR
"protein energy malnutrition"[All Fields]) yields 164
Bibliographic search included WHO policy papers,
personal communication, original articles and review
articles written in English, French and Spanish. The fol-
lowing retrieved studies were included: longitudinal
studies, randomized controlled trials, reviews or other
comparative studies. Case reports were excluded. The
included studies were then reviewed by two authors, and
major findings reported. No ethical approval was re-
quired as this is a comprehensive paper without primary
data collection.
Results
Of the studies retrieved from the above-mentioned elec-
tronic database, 13 epidemiological studies and 6 (sys-
tematic reviews)/meta-analyses were included in this
review. They are summarized in the Table 1 below:
The studies included in this review revealed the
following outcomes:
Synergistic effects between TB, immunosenescence and
DM
Immunosenescence and DM act synergistically to limit
macrophage activation, which in turn decreases IL 12
and consequently IFN gamma, which is believed to play
a central role in CMI against intracellular infection pri-
marily by acting on Natural Killer (NK) and T cells. This
is achieved through the following mechanisms:
Mononuclear phagocytes
Activated mononuclear phagocytes stimulate granuloma
formation in response to infection. As humans age, the
macrophage capacity for phagocytosis diminishes, which
is why the oxidative burst is compromised in elderly per-
sons [30]. In a study involving TB patients, alveolar mac-
rophages were less activated and had lower hydrogen
peroxide production in those with DM comorbidity [31].
Additionally, in aged individuals the up-regulation of
the major histocompatibility complex (MHC) class I and
II expression as well as the antigen presentation capacity
are reduced in dendritic cells, [32] which as a corollary
diminishes interleukin 2 production and reduces T-cell
proliferation. DM has been shown to hamper receptor-
bound material, [33] which further limits the role of
antigen-presenting cells in lymphocyte activation by pre-
venting the phagocytes from binding and internalizing
the antigen, for processing and presentation via their Fc
receptors.
Natural Killer (NK) cells
It is well known that in elderly humans NK cells show
diminished cytotoxic capacity on a 'per cell' basis [34].
Other aspects of NK cell function, such as the secretion
of IFN-γ in response to IL-2 and IL 12 are also compro-
mised in the aging population [35]. The decrease in
IFN-γ produced by NK cells is further emphasized in in-
dividuals with concomitant DM.
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Table 1 Table summarizing the findings of the studies used in this review
First
author
Year of
publication
Study design and sample size Main exposure(s) of
interest
Main outcome(s)
of interest
Main results and Remarks
Peleg AY 2007 Literature review Glycaemic control Risk of common
community
acquired infections
Further research is needed to
improve understanding of the
role of diabetes and glycaemic
control in the pathogenesis and
management of community and
hospital acquired infections
Leung CC 2008 Cohort study 42,116 clients
aged 65 years or more,
Diabetes mellitus TB Among diabetic subjects, higher
risks of active, culture-confirmed,
and pulmonary but not
extrapulmonary tuberculosis were
observed, with baseline hemoglobin
A1c ≥7 % (vs. <7 %)
Dick
Menzies
2011 Review article LTBI TB LTBI therapy should be given only
to those with positive tests for LTBI.
Underutilized, particularly in LMIC
Matthew J.
Magee
2014 cohort of 1366 adult patients DM MDR TB DM did not impact culture
conversion rates in a clinically
meaningful way, but smoking did.
Holt PR 2001 Review/Perspective Elderly population Malabsorption Nutrition may be compromised
rapidly by the reduction in food
intake or malabsorption that
accompanies many of the
conditions that cause diarrhea
in the elderly
Cruz-
Hervert LP
2012 Cross sectional study of 893
65 years of age or older.
65 years of age or older Clinical and
epidemiological
consequences of
pulmonary
tuberculosis
Untimely and difficult diagnosis
and a higher risk of poor outcomes
even after treatment completion
emphasize the need for specific
strategies in this vulnerable group.
J. Peter
Cegielski
2012 Cohort 1982–1992 of 14,189
adults
BMI TB Population's nutritional profile is
an important determinant of TB
incidence.
Nyadzayo 2014 (still
in press)
Cohort study 410 adults TB Recovery from
moderate
malnutrition
Moderately malnourished adults are
less likely to recover their nutritional
status compared to non-TB patients
when under supplementary treatment
Kurbatova,
E. V
2012 Cohort study of 1416 adults
in 5 countries
predictors of initial
sputum culture
conversion in MDR TB
treatment
Lower but not significant unadjusted
rate of sputum culture conversion
among patients with DM
Matthew J.
Magee
2014 Cohort study of 1,366 adult
patients in Georgia
MDR TB treatment in
DM patients
culture conversion
among patients
with multidrug-
resistant (MDR)-TB
In adjusted analyses, DM did not
impact culture conversion rates in
a clinically meaningful way
María
Eugenia
Jiménez-
Corona
2013 Cohort study of 1262 patients
with pulmonary TB in Mexico
Patients with DM clinical
consequences of
pulmonary
tuberculosis
Patients with DM and pulmonary
TB had more severe clinical
manifestations, delayed sputum
conversion, a higher probability of
treatment failure and recurrence
Meghan A
Baker
2011 Systematic review and
meta-analysis.
quantitative summary
evidence for the impact
of diabetes on
tuberculosis outcomes
DM increases the risk of treatment
failure and death combined, death
and relapse among patients with
tuberculosis.
Christie Y
Jeon
2008 13 observational studies
(n = 1,786,212 participants)
with 17,698 TB cases
Patients with DM Active TB disease Meta-analysis shows that DM
increases the risk of TB, regardless
of different study designs,
background TB incidence or
geographic region of the study.
Stevenson
CR
2007 Review Patients with DM Active TB disease All studies identified statistically
significant associations, with a
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T lymphocytes
As humans age, the thymus naturally atrophies and the
ability of stem cells to undergo clonal proliferation de-
clines. This further emphasizes the reduced secretion of
IL IFN gamma by the macrophages and NK in ageing in-
dividuals with DM. The inability to produce adequate
numbers of mature T lymphocytes compromises the
ability of elderly individuals to respond effectively to
infections.
As T cells age, they also lose their capacity to produce
and respond to IL-2 and IL 12 as major inducers of Th1
type responses, resulting in increased susceptibility to
bacterial and viral infections and neoplasias among
elderly persons, compared to young adults [36]. An add-
itional synergistic factor is the impaired host resistance
in individuals with DM. Namely, lymphocyte prolifera-
tion in response to phytohaemagglutinin has been found
to be weak in patients with poorly controlled DM [37].
Resistance to mycobacterial infections is mediated
largely by T helper type 1 (Th1) cells and their cyto-
kines, whilst Th2 cells and their cytokines correlate with
disease susceptibility and pathology in TB [38]. Whilst
Th1 cytokines induces Th1 activity and block Th2 activ-
ity, [39, 40] Th2 cytokines promote Th2 activity while
inhibiting Th1 activity [41]. The decrease in Th1:Th2 ra-
tio may be of great importance in age-related immune
changes, since Th1 mainly induces maturation and acti-
vation of the cytotoxic T lymphocytes which decrease
with ageing, [42] while Th2 induces increased B lympho-
cyte immunoglobulin production which increases with
ageing [43]. A recent study showed that diabetic TB pa-
tients had lower Th1:Th2 cytokine ratios and a higher
Th2 bias. Also, the concentration of IL-4 alone was sig-
nificantly higher in diabetic TB patients compared to
non-diabetic TB patients and healthy subjects. As higher
concentration of IL-4 is also found in aged individuals
due to dysregulation between Th1 and Th2, [44] this
synergistic elevation in IL-4 secretion may contribute
to increased pathogenesis in diabetic TB patients be-
cause IL-4 impairs anti-microbial activity of infected
cells and increases availability of iron to intracellular
M. tuberculosis.
Elderly DM patients also show an altered T cytokine
production pattern. In aged individuals, lymphocytes
produce less IFN-γ, the main T-helper-1 (Th1) cytokine
and the main mediator of protective immunity against
TB. DM in aged individuals might further adversely
affect T-cell production of interferon γ, especially in
high-glucose conditions. Consequently, T cell growth,
function and proliferation is affected, further comprom-
ising effective mononuclear phagocytes and NK cell me-
diated response to tuberculosis.
Table 1 Table summarizing the findings of the studies used in this review (Continued)
1.5- and 7.8-fold increase in risk
or odds of TB in diabetic patients.
Inadequate adjustment of
potential major confounders.
Nijland HM 2006 1 prospective pharmacokinetic
study (n = 17 adult patients
Patients with TB-DM
comorbidity
Effect on plasma
rifampicin levels
Study showed 53 % lower rifampicin
exposure (AUC0–6 h) in TB-DM
patients, compared to TB only
patients.
Meghan A
Baker
2012 Prospective study Patients with DM Active TB and
severe TB
The risk of developing tuberculosis
increased among those with
increasing diabetes severity.
Brendan K.
Podell,
2012 60 guinea pigs were randomly
assigned to Mtb infected and
sucrose-fed (n = 20), Mtb infected
and water-fed (n = 20), uninfected
and sucrose-fed (sucrose control,
n = 10) and uninfected and
water-fed (uninfected control,
n = 10).
Hyperglycaemia Severity of
tuberculosis infection
in non-diabetic
guinea pigs
The exacerbation of insulin
resistance and hyperglycaemia by
Mtb infection alone may explain
why TB is more severe in diabetics
with poorly controlled
hyperglycaemia compared to non-
diabetics and patients with properly
controlled blood glucose levels.
J. Peter
Cegielski
2012 A prospective study of 13,419
adults from 25 to 72 years of age
different levels of
nutritional status
Incident cases of TB Population's nutritional profile is an
important determinant of TB
incidence, after controlling for
socio-economic factors, excess
alcohol consumption, smoking,
and DM
Yung-Feng
Yen
2016 Population-Based Follow-Up
Study of 1608 patients
(<18.5), normal
(18.5–24.9), and
overweight (≥25).
TB treatment
outcome
Insufficient body weight was
associated with higher risks of
TB-specific and non-TB-specific
mortality during TB treatment,
particularly in male patients.
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Studies show that when the glycated hemoglobin
(HbA1c) is <8.0 %, the proliferative function of CD4 T
lymphocytes and their response to antigens remains un-
impaired [14]. This was also illustrated in a study of
4690 elderly diabetic patients in Hong Kong: those with
haemoglobin A1c > 7 % had a three times higher risk of
active tuberculosis compared with those with haemoglo-
bin A1c < 7 % (HR 3 · 11; 95 % CI 1 · 63–5 · 92) [45].
In Taiwan, a prospective study of 17 715 Taiwanese
persons selected from the general population sug-
gested that the participants’ risk of tuberculosis in-
creased as the number of complications of DM
increased (P = 0.0016), with >3-fold risk among those
with ≥2 diabetes-related complications (odds ratio,
3.45; 95 % CI, 1.59–7.50) [46].
Aside from clinically manifested diabetes, a study on
infected guinea pigs showed that non-diabetic hypergly-
caemia has the potential to significantly worsen active
TB, [47] suggesting that inflammation-associated insulin
resistance during TB infection may be an additional fac-
tor contributing to hyperglycaemia.
Synergistic interactions between TB, ageing and nutritional
status
The lower disease-fighting capacity of the elderly, espe-
cially diabetics, which is partly attributable to the de-
regulation of the immune system and the greater
secretion of macrophage pro-inflammatory cytokines in
response to antigenic challenge, also leads to greater or
longer-lasting body metabolic changes in this population
group [48].
Whilst no change was found in T cell function in very
healthy elderly individuals without nutritional deficit,[48]
micronutrient deficiency has been shown to further
lower immunity by affecting all parameters of CMI, well
beyond the effect attributable to the ageing process
alone, resulting in increased susceptibility to infectious
diseases [49]. The decrease in immune functions
strongly correlates with the level of nutritional defi-
ciency, [50] with severely immuno-deficient aged indi-
viduals suffering from severe PEM, a condition marked
by insufficient protein and calorie intake. Whilst PEM
significantly affects innate immunity in the elderly, [51]
it chiefly impairs CMI. The resultant atrophy of the thy-
mus [52] reduces the number of circulating T cells,
thereby decreasing the effectiveness of the memory re-
sponse to antigens. PEM is also associated with signifi-
cantly reduced vaccine antibody responses in the elderly
population [53].
The link between body weight and TB has been in-
creasingly reported in scientific literature. A systematic
review from 2009 found a strong and consistent log-
linear relationship between TB incidence and BMI
across a variety of settings, with different levels of TB
burden [54]. In populations where protein insufficiency
is common, it may contribute substantially to TB inci-
dence [55]. Namely, a recent large prospective study
showed that the population-estimated hazard of devel-
oping TB for persons with low BMI (<18.5 kg/m2) was
HR 12.4 (95 % CI: 5.7, 26.9) greater compared to persons
with normal BMI, after controlling for socio-economic
factors, excess alcohol consumption, smoking and dia-
betes mellitus [28].
Also, a cohort study in Taiwan involving patients with
a mean age of 64.6 years found that insufficient body
weight was associated with higher risks of TB-specific
and non-TB-specific mortality during TB treatment, par-
ticularly in male patients, after adjusting for age, sex,
clinical findings, and comorbidities [56].
Synergistic association between DM and PEM
Insulin is a strongly anabolic hormone for protein, [57]
fat, [58] and glycogen [59] accrual, and deficiency or re-
sistance to insulin may also promote PEM. In addition,
comorbidities that diabetic patients are more prone to,
such as catabolic events including myocardial infarc-
tions, strokes, infection, ischemic atrophy, [60, 61] cuta-
neous ulcers and gangrene [62] in the extremities
increase the likelihood of PEW/ PEM. Studies have
demonstrated a higher frequency of protein-wasting in
diabetic patients compared to nondiabetic end-stage
renal disease patients on maintenance dialysis therapy
[63–65].
It is noteworthy that ageing is also associated with de-
creased capacities to cope with metabolic changes result-
ing from underfeeding and/or nutritional responses to
disease [66]. A personal communication by Nyadzayo-
Rossi (who carried out a not yet published cohort study
in moderately undernourished adults in Zimbabwe)
found that moderately undernourished adult TB patients
appear to be at a higher risk of not responding to nutri-
tional treatment compared to those not affected by TB.
This finding highlights the need for preventing undernu-
trition in aged individuals in order to improve TB con-
trol, while considering the impact on glycaemic control.
PEM in turn contributes to increased frailty due to
depletion of protein body reserves and consequent sus-
ceptibility to recurrent TB episodes or other infections
in these individuals, already suffering from a lower pro-
tection against free radicals. Consequently, PEM is com-
pounded in aged individuals, who suffer from reduced
immune responses [49]. Moreover, there is also a possi-
bility of increased TB drug malabsorption in elderly pa-
tients [67]. This may be accentuated by PEM, which in
turn impairs drug absorption, [68] thereby adding a new
dimension to the growing problem of MDR TB. In 2011,
a meta-analysis estimated that DM patients have a risk
ratio (RR) for the combined outcome of failure and
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death of 1.69 (95 % CI, 1.36 to 2.12) and an increased
risk of relapse (RR, 3.89; 95 % CI, 2.43 to 6.23) after
TB treatment [69]. Several studies have reported a
high prevalence of DM among patients with MDR-
TB, [70–72] including an association between DM
and MDR-TB after adjusting for confounding factors
[73]. However, 4 studies in disparate settings showed
no significant increased risk [74–76].
According to WHO estimates, less than 50 % of all
cases worldwide are currently diagnosed and treated
[77]. Furthermore, due to compromised immunity, such
as HIV infection, atypical clinical and radiological fea-
tures in elderly individuals with DM and PEM as well as
false negative tuberculin reactions may be very frequent
[78]. A recent study underscored how untimely and dif-
ficult diagnosis, along with a higher risk of poor out-
comes even after treatment completion emphasizes the
need to devise specific strategies for this vulnerable
group [79].
TB drug management in diabetic patients
Diabetes negatively affects TB drug treatment, especially
in patients with poor glycaemic control, which may be
attributed to altered drug pharmacokinetics in DM. DM
affects protein, lipid and carbohydrate metabolism as
well as various aspects of pharmacokinetics. These in-
clude changes in absorption for several drugs adminis-
tered via the subcutaneous and intramuscular route, as
well as the oral route due to disordered gastric emptying
(generally abnormally slow in 30–50 % DM patients, also
slower during hyperglycaemia and accelerated during
hypoglycaemia) [80]. Furthermore, the impact of DM on
enzymes/transporters involved in drug biotransform-
ation, as well as the reduction of plasma protein binding
and displacement of drugs from their protein binding
sites (due to higher circulating amount of free fatty acids
in DM) [76] also affects drug pharmacokinetics. A recent
study on TB showed that disease progression in guinea
pigs with impaired glucose tolerance was similar to that
of non-diabetic controls in the early stages of infection
but got more severe by day 90 [81]. Drug toxicity risk
may be higher due to excessive drug accumulation in
the body, as a result of diabetic nephropathy.
A study involving 17 Indonesian patients with TB-DM
comorbidity found 53 % lower plasma concentrations of
rifampicin in these patients, compared to patients with TB
only. These pharmacokinetic changes have been associ-
ated with clinical failure and acquired drug resistance [82].
These observations are congruent with those of a study
from Mexico published in 2013 which reported that the
proportion of TB patients on first line TB therapy who
converted sputum cultures to negative ≥60 days of treat-
ment was significantly greater in patients with DM
(45.9 %) compared to those without DM (37.2 %) [83].
MDR TB drug management in diabetic patients
The influence of DM on MDR-TB patient outcomes is
understudied [84]. Findings from a study on MDR-TB in
2012 involving diabetic patients from five countries, re-
ported a lower non-significant univariate rate ratio (HR
0.76, 95 % CI 0.54–1.06) of sputum culture conversion
among patients with DM [85]. These findings are con-
gruent with those of a recent cohort study of adult pul-
monary MDR-TB patients from Georgia, according to
which, after adjusting for important confounding factors,
the rate of sputum culture conversion and the risk of
poor treatment outcome was similar in MDR-TB pa-
tients with and without DM, adjusted HR estimate (0.95,
95 % CI 0.71–1.28).
A bi-directional relationship has also been observed,
as ethionamide or protionamide have been shown to
make DM management in patients undergoing treat-
ment with the above drugs more difficult [66].
Research gaps
Association between DM and PEM in the elderly population
Randomized clinical trials exploring the optimal
methods of monitoring for PEM as well as prevention
and treatment of these disorders in diabetic elderly pa-
tients are clearly needed.
Association between DM and MDR TB
At a biological level, there is a need of a better under-
standing of diabetes-related immunopathogenic mecha-
nisms reinforcing immunosenescence, and mechanisms
by which DM may lead to MDR TB.
The impact of DM on TB and MDR TB treatment
outcomes
Despite extensive research efforts to elucidate the ef-
fects of DM on pharmacokinetics and pharmacodynam-
ics and the significant progress made in this area, the
available information is nonetheless insufficiently clear.
Additional clinical studies are needed to fully unravel
the clinical significance of these effects. DM - mediated
changes in the pharmacokinetics of a particular drug
must not be generalized to include other drugs, as
changes are drug-specific.
Biological mechanisms potentially contributing to TB
and MDR TB treatment failure as well as those interfer-
ing with glucose control during rifampicin and ethion-
amide therapy must be elucidated in conjunction with
further epidemiological studies exploring the impact of
DM on both first line and second line treatments.
In contrast to experimental animal models, DM-
related effects on pharmacological properties of drugs
in human subjects have not been sufficiently elabo-
rated. Further larger prospective research aimed at
understanding the diabetes-mediated changes as well
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as the sources of the variability is required to help
optimize drug management and improve clinical out-
comes in DM patients [86].
Furthermore, in order to avoid future discrepancies
between individual clinical studies, as well as between
ex vivo and clinical studies on this issue, due atten-
tion should be paid to adequate selection of test sub-
jects, the type, severity and duration of the disease,
histopathological characteristics, as well as other im-
portant factors such as medication use, protein intake,
age, sex and obesity.
Association between low BMI and TB
Although a large prospective study found that persons
with low BMI (<18.5 kg/m2) are at higher risk of devel-
oping active TB compared to those with normal BMI,
after controlling for socio-economic factors, excess alco-
hol consumption, smoking, and diabetes mellitus, it may
also be useful to adjust for micronutrient deficiencies.
Also, this area of research would benefit from a case
control study, wherein active TB elderly patients are
compared to non active TB patients in terms of BMI,
using the WHO BMI categorization [87]: <16 = severe
malnutrition, 16–16.99 = moderate malnutrition, 17–
18.49 = mild malnutrition; 18.5-24.99 = normal weight,
25–29.99 = overweight; ≥30 = obese.
Furthermore, it may also be necessary to explore more
thoroughly whether TB patients have more difficulties in
recovering from malnutrition compared to non-TB pa-
tients, a recommendation which is also stipulated in the
WHO nutritional guidelines for TB [88].
Clinical diagnostic algorithm for elderly patients with DM
Reducing the duration of infectiousness will require estab-
lishment of an appropriate clinical diagnostic algorithm
and adaptation of clinical guidelines to address elderly pa-
tients with DM. Clinical research is warranted to establish
a clinical diagnostic algorithm as well as clinical manage-
ment guidelines targeting this population.
Prevention of active TB
Twenty randomized trials involving treatment of latent
TB infection (LTBI) to prevent active TB in more than a
dozen countries demonstrated that isoniazid (INH) ad-
ministered for at least 6 months in persons with LTBI
reduced subsequent TB incidence by 25 to 92 % [89];
the differences were mainly attributed to variation in
treatment completion. In the elderly population with
DM and PEM, the effectiveness of an INH regimen
still needs to be determined, along with exploring its
high potential for hepatotoxicity and the pharmaco-
epidemiology of INH interaction with other drugs.
Bi-directionality of TB and DM
Studies have shown that TB can even cause DM in those
not previously known to be diabetic, with TB patients
showing higher rates of glucose intolerance than com-
munity controls [33, 90, 91]. This may not only lead to a
global explosion of TB cases, but also DM cases. Fur-
thermore, determining the bi-directionality of TB and
DM and the potential of DM to fuel not only a TB, but
potentially a MDR TB epidemic will need to be
investigated.
Discussion
At a global level, the lethal cocktail of ageing population
with PEM, latent TB and concomitant diabetes mellitus
sets the stage for increased TB transmission that may
fuel a TB epidemic and possibly a MDR TB epidemic.
Reducing TB transmission in low, middle and high in-
come settings will require a multipronged approach. In
middle and higher income countries, the increasing
number of people residing in nursing and chronic
disease facilities places residents at greater risk for devel-
oping active TB than elderly persons living in the com-
munity, with the potential of spilling over within the
community. In low-income countries, higher life expect-
ancy combined with an already high prevalence of PEM
may fuel an unprecedented TB and possibly an MDR TB
epidemic.
This begs for an integrative framework for enhanced
TB control and prevention among aged diabetics as well
as a stringent screening of glycaemic responses in TB
patients at the time of diagnosis, even if diagnostic cri-
teria for diabetes are not met [84, 92] This integrative
framework should be tailored to the contexts of industri-
alized and middle - income countries. To this end, the
working definition of “old” must first be established per
setting. Most industrialized nations have accepted the
chronological age of 65 years as a definition of 'elderly'
or older person, [93] whilst in sub-Saharan Africa a
MDS/WHO established the age of 50 years as a
working definition of “old.” This will be all the more
relevant for low- to middle-income countries, includ-
ing India and China, which have the highest burden
of TB and are experiencing the fastest increase in
diabetes prevalence [16].
As an adjunct, PEM management should be strength-
ened. PEM management research must also encompass
a better appreciation of the nutritional status of the eld-
erly population, especially in resource-poorer countries.
In addition, another salient area of research would be to
explore the protective effect of higher BMI in preventing
development of active TB or improving disease outcome.
If these observations are confirmed, policies regarding
isoniazid preventive treatment could be revisited because
the potential benefit would be much lower among
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elderly persons with medium to high BMI. Moreover,
WHO guidelines for TB nutritional support must estab-
lish a calorie intake threshold for aged diabetic patients.
Conclusion
The still poorly elucidated tripartite association involving
TB, PEM, and DM in the ageing population threatens to
place a major burden on the public health system. A num-
ber of epidemiological and clinical gaps must be addressed
to curb transmission. Enhanced PEM management, espe-
cially in resource-poorer settings, the development of a
clinical diagnostic algorithm as well as clinical guidelines
for this population are urgently needed. To thwart an ex-
plosion of TB and potential MDR TB and DM epidemics,
the transmission dynamics should be examined.
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